Sarepta Therapeutics Inc $23.20

up +0.70


26/8/2014 05:15 PM  |  NASDAQ : SRPT  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get SRPT Trend Analysis - it has underperformed the S&P 500 by 55%

Partner Headlines

  1. Biotechs That Might Benefit From Ebola

    Benzinga
  2. Tekmira Ebola Drug Hold Lifted By FDA, Stock Soars

    IBD
  3. Benzinga's Top #PreMarket Gainers

    Benzinga
  4. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga
  5. Sarepta Up 12% As FDA Is 'Actively Engaged' On Drug Application

    Benzinga
  6. Morning Market Losers

    Benzinga
  7. Benzinga's Top #PreMarket Losers

    Benzinga
  8. Shares of Sarepta Therapeutics Plummet on CSO Termination

    Benzinga
  9. Mid-Afternoon Market Movers For July 10, 2014

    Benzinga
  10. Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following ...

    Benzinga
  11. Lumber Liquidators Falls On Weak Forecast; Zumiez Shares Spike Higher

    Benzinga
  12. Markets Open Lower; Family Dollar Profit Misses Estimates

    Benzinga
  13. Morning Market Losers

    Benzinga
  14. UPDATE: Sarepta Therapeutics Announces $100M Proposed Public Offering of ...

    Benzinga
  15. Five Star Stock Watch: Sarepta Therapeutics

    Benzinga
  16. Benzinga's Top Upgrades

    Benzinga
  17. Mid-Afternoon Market Update: Markets Remain in the Green as Moneygram Falls ...

    Benzinga
  18. Sarepta Revives Hopes For Muscular Dystrophy Drug

    IBD
  19. Mid-Day Market Update: AMD Surges After Upbeat Results; Acacia Research ...

    Benzinga
  20. Benzinga's Volume Movers

    Benzinga
  21. Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit

    Benzinga
  22. Morning Market Movers

    Benzinga
  23. Stock Futures Defend Thin Gains; Halliburton And Revlon Climb

    IBD
  24. Benzinga's Top #PreMarket Gainers

    Benzinga
  25. Barron's Recap: Sunny Skies For Home Depot

    Benzinga
  26. Prosensa Muscular Dystrophy Data Send Stock Rising

    IBD
  27. Benzinga's Top #PreMarket Losers

    Benzinga
  28. UPDATE: Sarepta Announces Positive Safety Results from Phase I Trial of ...

    Benzinga
  29. UPDATE: JMP Downgrades Sarepta, Data Considered Weak and Overstated

    Benzinga
  30. Needham Upgrades Sarepta, Says Stock Underalued Even In Conservative Case

    Benzinga
  31. Is The Market On Drugs?

    Benzinga
  32. Mid-Morning Market Update: Markets Mostly Lower; Goldman Sachs Posts Upbeat ...

    Benzinga
  33. Morning Market Movers

    Benzinga
  34. Benzinga's Top #PreMarket Gainers

    Benzinga
  35. UPDATE: Sarepta Downgraded by Citigroup on Eteplirsen Early Approval Setback

    Benzinga
  36. Mid-Morning Market Update: Markets Mostly Lower; GE To Acquire Thermo Fisher ...

    Benzinga
  37. Morning Market Losers

    Benzinga
  38. Benzinga's Top #PreMarket Losers

    Benzinga
  39. UPDATE: Canaccord Genuity Downgrades Sarepta Therapeutics as FDA Talks ...

    Benzinga
  40. Market Wrap For November 26: Nasdaq Closes Above 4,000 For First Time Since ...

    Benzinga
  41. Mid-Afternoon Market Update: Markets Rise as NASDAQ Eyes Close Over 4, ...

    Benzinga
  42. UPDATE: Deutsche Bank Downgrades Sarepta Therapeutics Following FDA Announcement ...

    Benzinga
  43. Sarepta Plunges And Love Affair Ends (For Now)

    YCharts
  44. Sarepta sinks on FDA report

    IBD
  45. Market Wrap For November 12: Investors Continue to Speculate on the Fed's ...

    Benzinga
  46. Mid-Afternoon Market Update: Markets in the Red as American Airlines/US ...

    Benzinga
  47. Sarepta Therapeutics Plunges On Negative FDA Report

    IBD
  48. UPDATE: Piper Jaffray Downgrades Sarepta Therapeutics After FDA Reverses ...

    Benzinga
  49. Benzinga's Top #PreMarket Losers

    Benzinga
  50. Sarepta Therapeutics Announces FDA Considers NDA Filing for Eteplirsen ...

    Benzinga
Trading Center